Cargando…

Erratum to ‘Adjuvant endocrine therapy in HER2-positive breast cancer patients: systematic review and meta-analysis’: [ESMO Open Volume 6, Issue 2, April 2021, 100088]

Detalles Bibliográficos
Autores principales:	Peleg Hasson, S., Brezis, M.R., Shachar, E., Shachar, S.S., Wolf, I., Sonnenblick, A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Erratum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8233645/ https://www.ncbi.nlm.nih.gov/pubmed/34144779 http://dx.doi.org/10.1016/j.esmoop.2021.100158

Ejemplares similares

Adjuvant endocrine therapy in HER2-positive breast cancer patients: systematic review and meta-analysis
por: Peleg Hasson, S., et al.
Publicado: (2021)

Erratum to ‘Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival’: [ESMO Open Volume 7, Issue 2, April 2022, 100409]
por: Miglietta, F., et al.
Publicado: (2022)

Impact of the OncotypeDX score and HER2 RNA PCR levels on HER2-low IHC levels in primary and metastasized tumors
por: Feldman, Didi, et al.
Publicado: (2023)

Erratum, Vol. 12, April 2 Release
Publicado: (2015)

Alpelisib Efficacy in Hormone Receptor-Positive HER2-Negative PIK3CA-Mutant Advanced Breast Cancer Post-Everolimus Treatment
por: Raphael, Ari, et al.
Publicado: (2022)

From ESMO TAT 2021
por: Killock, David
Publicado: (2021)

From the ESMO Congress 2021
por: Sidaway, Peter
Publicado: (2021)

Erratum to ‘Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario’: [ESMO Open Volume 7, Issue 2, April 2022, 100406]
por: Cantini, L., et al.
Publicado: (2022)

Erratum to ‘Longitudinal characterisation of haematological and biochemical parameters in cancer patients prior to and during COVID-19 reveals features associated with outcome’: [ESMO Open Volume 6, Issue 1, February 2021, 100005]
por: Lee, R.J., et al.
Publicado: (2021)

ESMO 2021—highlights in colorectal cancer
por: Weiss, Lukas
Publicado: (2022)

Erratum to ‘Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial’: [ESMO Open Volume 6, Issue 3, June 2021, 100101]
por: Choueiri, T.K., et al.
Publicado: (2021)

Rapid Implementation of Telemedicine During the COVID‐19 Pandemic: Perspectives and Preferences of Patients with Cancer
por: Hasson, Shira Peleg, et al.
Publicado: (2021)

Erratum: A miRNA-based signature predicts development of disease recurrence in HER2 positive breast cancer after adjuvant trastuzumab-based treatment
por: Du, F., et al.
Publicado: (2016)

Erratum, Vol. 10, April 26 Release
Publicado: (2013)

Erratum, Vol. 10, April 25 Release
Publicado: (2013)

Erratum, Vol. 12, April 30 Release
Publicado: (2015)

Erratum, Vol. 10, April 4 Release
Publicado: (2013)

Erratum, Vol. 16, April 18 Release
Publicado: (2019)

Erratum, Vol. 13, April 28 Release
Publicado: (2017)

Erratum to: Dual HER2 blockade: preclinical and clinical data
por: Patel, Tejal A, et al.
Publicado: (2014)

OTHR-03. Brain Metastasis Among Ovarian Cancer Patients
por: Limon, Dror, et al.
Publicado: (2021)

Kambô-Induced Systemic Inflammatory Response: A Case Report of Acute Disease Progression of Cholangiocarcinoma
por: Peleg Hasson, Shira, et al.
Publicado: (2021)

Erratum, Vol. 10, April 11, 2013 Release
Publicado: (2014)

Erratum, Vol. 20, April 13, 2023 Release
Publicado: (2023)

Erratum to ‘Germline-focussed analysis of tumour-only sequencing: recommendations from the ESMO Precision Medicine Working Group’: [Annals of Oncology 30 (2019) 1221–1231]
por: Mandelker, D., et al.
Publicado: (2021)

Comparison of Patient Susceptibility Genes Across Breast Cancer: Implications for Prognosis and Therapeutic Outcomes
por: Peleg Hasson, Shira, et al.
Publicado: (2020)

Implementation of Comprehensive Genomic Profiling in Ovarian Cancer Patients: A Retrospective Analysis
por: Peleg Hasson, Shira, et al.
Publicado: (2022)

Clinicopathological factors associated with HER2-positive gastric cancer: A meta-analysis: Erratum
Publicado: (2017)

Erratum to: Lapatinib access into normal brain and brain metastases in patients with Her-2 overexpressing breast cancer
por: Saleem, Azeem, et al.
Publicado: (2017)

ESMO20 YO for YO: highlights on adjuvant CDK4/6 inhibitors in early hormone receptor-positive/HER2-negative breast cancer
por: Matikas, A., et al.
Publicado: (2020)

Erratum to: Antibodies Against Human BLyS and APRIL Attenuate EAE Development in Marmoset Monkeys
por: Jagessar, S. Anwar, et al.
Publicado: (2012)

ESMO 2021—my top three abstracts in breast cancer
por: Suppan, Christoph
Publicado: (2022)

Erratum to ‘Reply to: Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients’: [ESMO Open Volume 7, Issue 1, February 2022, 100393]
por: Beechinor, R., et al.
Publicado: (2022)

Erratum for Multiple Endocrine Neoplasia Type 1 with Functional Parathyroid Cysts
por: Koyama, Nobuyuki, et al.
Publicado: (2022)

Erratum to: Importance of formalin fixing conditions for HER2 testing in gastric cancer: immunohistochemical staining and fluorescence in situ hybridization
por: Yamashita-Kashima, Yoriko, et al.
Publicado: (2014)

Erratum for Euro Surveill. 2021;26(42)
Publicado: (2021)

Erratum for Euro Surveill. 2021;26(31)
Publicado: (2021)

Erratum for Euro Surveill. 2021;26(40)
Publicado: (2021)

Erratum for Euro Surveill. 2021;26(40)
Publicado: (2021)

Erratum for Euro Surveill. 2021;26(41)
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_1u86ivlimagk7jrrc3iu097th0